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ABSTRACT
Introduction: Several drugs targeting the GABAergic system are used in the treatment of epilepsy,
but only one drug targeting glutamate receptors is on the market. This is surprising because an
imbalance between excitatory and inhibitory neurotransmission lies at the core of the pathophysiol-
ogy of epilepsy. One possible explanation is that drug development has been directed towards the
synthesis of molecules that inhibit the activity of ionotropic glutamate receptors. These receptors
mediate fast excitatory synaptic transmission in the central nervous system (CNS) and their blockade
may cause severe adverse effects such as sedation, cognitive impairment, and psychotomimetic
effects. Metabotropic glutamate (mGlu) receptors are more promising drug targets because these
receptors modulate synaptic transmission rather than mediate it.
Areas covered: We review the current evidence that links mGlu receptor subtypes to the pathophy-
siology and experimental treatment of convulsive and absence seizures.
Expert opinion: While mGlu5 receptor negative allosteric modulators have the potential to be protec-
tive against convulsive seizures and hyperactivity-induced neurodegeneration, drugs that enhance
mGlu5 and mGlu7 receptor function may have beneficial effects in the treatment of absence epilepsy.
Evidence related to the other mGlu receptor subtypes is more fragmentary; further investigations are
required for an improved understanding of their role in the generation and propagation of seizures.
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1. Introduction
An imbalance between excitatory and inhibitory neurotrans-
mission is one of the key mechanisms in the development of
epileptic seizures, and this provides the rationale for the use
of drugs that enhance inhibition by increasing extracellular
GABA concentration (e.g., valproate, tiagabine, vigabatrine) or
activating GABAA receptors (e.g., benzodiazepines). On the
other side of the coin, only one drug that reduces excitation
by specifically targeting glutamate receptors, the α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) recep-
tor antagonist perampanel, is currently used in the treatment
of focal epilepsy [1]. This is quite surprising if one considers
the higher density of excitatory pyramidal neurons with
respect to inhibitory GABAergic interneurons in the cerebral
cortex and hippocampus (e.g., about 85% vs. 15% of the
overall neuronal population in particular regions of the cere-
bral cortex, respectively). Glutamate receptors are divided
into two major superfamilies: (i) ionotropic (iGlu) receptors,
which form membrane cation channels; and (ii) metabotropic
(mGlu) receptors, which are coupled to effectors via
G proteins. iGlu receptors include AMPA, NMDA (N-methyl-
D-aspartate), and kainate receptors, and they are all formed
by the heteromeric assembly of four subunits, which deter-
mine the ion selectivity and kinetic properties of the ion
channels. AMPA-gated ion channels are selectively permeable
to Na+ ions at most of the excitatory synapses because of the
presence of the GluA2 subunit, which prevents Ca2+ influx
through the channel. In contrast, NMDA receptors are highly
permeable to Ca2+ ions, but they are inhibited by physiologi-
cal concentrations of extracellular Mg2+ [2]. Membrane depo-
larization removes the Mg2+ blockade of the NMDA-gated ion
channel, thereby allowing a large influx of extracellular Ca2+
in neurons when NMDA receptors are activated by glutamate
in the presence of the co-agonist, glycine [2,3]. Activation of
NMDA receptors is a key event in the induction of activity-
dependent synaptic plasticity (i.e., long-term potentiation
and long-term depression of excitatory synaptic transmission)
[4], and is also involved in the induction of electrical kindling
[5,6], which is a model of epileptogenesis, i.e. gradual process
by which a normal brain is biased towards the generation of
epilepsy. One of the reasons why drugs that primarily block
iGlu receptors are not currently used in the treatment of
epilepsy (with the notable exception of perampanel) is that
iGlu receptors mediate fast excitatory synaptic transmission,
and chronic pharmacological blockade of these receptors
may cause a sustained depression of synaptic transmission
and an impairment of activity-dependent synaptic plasticity
resulting in cognitive dysfunction. In addition, pharmacologi-
cal inhibition of NMDA receptors may produce psychotomi-
metic effects, as typically observed with the slow NMDA
channel blockers, ketamine and phencyclidine [7].
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As opposed to iGlu receptors, mGlu receptors do not med-
iate but rather ‘modulate’ synaptic transmission acting at
different levels of the tripartite synapse formed by the junc-
tion of axon terminals, dendritic spines, and astrocytes [8,9].
This shifts attention to mGlu receptors as candidate drug
targets in the experimental treatment of epilepsy.
2. Metabotropic glutamate receptors and epilepsy
mGlu receptors are G protein-coupled receptors activated by
glutamate and are involved in the modulation of synaptic
transmission. They are mainly expressed in the central nervous
system (CNS) and consist of eight subtypes divided into three
groups based on amino acid sequence, pharmacological prop-
erties, and signaling transduction pathways [10]. Specifically,
group I comprises mGlu1 and mGlu5 receptors, which are
expressed primarily at postsynaptic sites and are coupled to
Gq/G11 proteins associated with stimulation of the phospholi-
pase C pathway. Their activation stimulates the hydrolysis of
phosphatidylinositol-4,5-bisphosphate, with the formation of
inositol-1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG).
InsP3 and DAG enhance intracellular Ca
2+ release and activate
protein kinase C, respectively. Group II comprises mGlu2 and
mGlu3 receptors coupled to Gi/Go proteins, which transduce the
signal via inhibition of adenylyl cyclase and the modulation of
Ca2+ and K+ channels [11]. mGlu2 receptors are mainly localized
in nerve endings, where they negatively modulate neurotrans-
mitter release. mGlu3 receptors share the same presynaptic
localization, but, in addition, are also found in postsynaptic
elements, where they functionally interact with mGlu5 receptors
[12]. mGlu3 receptors are also expressed by astrocytes and
microglia, where they regulate the production of neurotrophic
factors and cytokines [9]. Finally, group III comprises mGlu4,
mGlu6, mGlu7, and mGlu8 receptors, which are coupled to
Gi/o proteins, and are expressed in presynaptic terminals
where they inhibit neurotransmitter release [13].
mGlu receptors form constitutive dimers composed of two
subunits linked by a disulfide bridge [14]. Each subunit contains
an extracellular orthosteric glutamate binding site (Venus
Flytrap domain, VFTD [15];), and allosteric binding sites located
within the seven transmembrane domains (7TMD) [16].
mGlu receptors are proposed as potential therapeutic tar-
gets for the treatment of neurologic and psychiatric disorders
and, thus, several compounds have been developed as sub-
type-selective mGlu receptor ligands [9,17].
Almost 30% of epileptic patients are resistant to current
pharmacological treatments [18], which include (i) inhibitors of
voltage-sensitive sodium channels, such as phenytoin, carba-
mazepine, oxcarbazepine, lamotrigine, and lacosamide; (ii)
GABA-mimetic drugs, such as benzodiazepines, barbiturates,
tiagabine, and vigabatrine; (iii) drugs interacting with the SV2A
synaptic vesicle protein, such as levetiracetam and brivarace-
tam; (iv) inhibitors of T-type voltage-sensitive calcium chan-
nels, such as ethosuximide; (v) inhibitors of the ▮2▮ subunit of
voltage-sensitive calcium channels, such as gabapentin and
pregabalin; and (vi) drugs showing pleiotropic mechanisms,
such as valproate, topiramate, zonisamide, and felbamate. In
addition, some conventional antiepileptic drugs such as phe-
nytoin and carbamazepine have a narrow therapeutic margin
and require therapeutic drug monitoring [19]. Thus, new anti-
epileptic drugs to ameliorate current therapies and to treat
the drug-resistant form of epilepsies are badly needed [20].
Owing to their modulatory function, mGlu receptors have
been implicated in the control of epileptic seizures [21], and
in mechanisms of epileptogenesis and hyperactivity-induced
neuronal damage [22,23].
Several selective agonists and antagonists of individual
mGlu receptor subtypes have been developed as valuable
tools to probe the role of mGlu receptors in physiology and
pathology, and some of these compounds have been, or are
currently being evaluated in clinical studies [24].
mGlu receptors could play a role in ictogenesis by increas-
ing or decreasing the effects caused by an excessive activation
of iGlu receptors [25], and some subtype-selective ligands
might improve the therapeutic effect of antiepileptic drugs
by modulating either excitatory or inhibitory neurotransmis-
sion [26]. The role of mGlu receptors in the pathophysiology
and treatment of epilepsy has been the subject of numerous
review articles in the last two decades [27–33].
The recent development of selective ligands of individual
mGlu receptor subtypes and their use in experimental animal
models of convulsive and absence seizures gave us the impetus
to further discuss the topic and comment on the potential use
of these compounds in the treatment of epilepsy.
2.1. Group I mGlu receptors and convulsive seizures
A large body of evidence has shown that mGlu5 receptors are
up-regulated in tissue specimens from patients suffering
from temporal lobe epilepsy, as well as in the rodent hippo-
campus after induction of limbic seizures. Eleonora Aronica
and her Associates were the first to show an increased
expression of mGlu5 (and mGlu3) receptors in hippocampal
astrocytes in a rat model of temporal lobe epilepsy [34].
These findings laid the groundwork for the study of mGlu
receptor expression in the hippocampus of patients suffering
from mesial temporal lobe epilepsy (TLE). Tang et al. [35]
found increases in mGlu1 and mGlu5 receptor immunoreac-
tivity in the dentate gyrus and CA1 region of TLE patients.
While mGlu1 immunoreactivity was exclusively localized in
postsynaptic elements, mGlu5 receptor immunoreactivity was
detected in both pre- and postsynaptic elements, as well as
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in astrocytes. Similarly, Blümcke et al. [36] observed an
increased expression of mGlu1▮ receptors in the dentate
gyrus of epileptic human and rat hippocampus. The up-
regulation of mGlu5 receptors was confirmed in more recent
studies examining hippocampal tissue specimens of drug-
resistant patients with TLE. The increase in mGlu5 receptor
expression was more prominent in patients with Ammon’s
horn sclerosis, where it correlated with mossy fiber sprouting
[37,38]. One possible interpretation of these data is that the
increased expression of mGlu5 receptors contributes to
mechanisms of maladaptive neuronal plasticity that sustain
seizures associated with TLE or, alternatively, might represent
a defensive mechanism of postsynaptic adaptation that tries
to control over-excitation [38].
Pharmacological blockade of either mGlu1 or mGlu5 receptors
is protective inmodels of convulsive seizures, suggesting that the
overall function of group-I mGlu receptors is to increase excit-
ability in neuronal circuits involved in the generation of convul-
sive seizures. Brian Meldrum and his Associates were pioneers in
the study of group-I mGlu receptor antagonists in models of
convulsive seizures. Intracerebroventricular (i.c.v.) injection of
the selective orthosteric mGlu1 receptor antagonists, LY367385
((+)-2-methyl-4-carboxyphenylglycine) andAIDA ((RS)-1-aminoin-
dan-1,5-dicarboxylic acid), was protective against a generalized
type of epilepsy with audiogenic seizures (DBA/2 mice). These
two compounds could also reduce sound-induced clonic seizures
when they were locally infused in the inferior colliculus of geneti-
cally epilepsy prone rats (GEPRs) [39]. Systemic administration
of 2-methyl-6-(phenylethynyl)-pyridine (MPEP) or (E)-6-methyl-
2-styryl-pyridine (SIB-1893), which behave as potent and selective
mGlu5 receptor negative allosteric modulators (NAMs), was also
protective against sound-induced seizures in DBA/2 mice [40].
NAMs interact with allosteric sites of mGlu receptors inhibiting
receptor activation regardless of the ambient concentrations of
glutamate. The anti-seizure activity of mGlu5 receptor blockers
was less prominent in the kindling model of epilepsy. Acute
treatment with MPEP could reduce seizures and afterdischarge
durations in kindled rats but only when combined with subpro-
tective doses of valproate or phenobarbital [41]. As expected,
molecules that antagonize both mGlu1 and mGlu5 receptors,
such as LY393053 (2-amino-2-(3-cis and trans-carboxycycl-
obutyl)-3-(9H-thioxanthen-9-yl) propionic acid), LY339764
((R.S)-2-amino-2-(4-carboxycyclobutyl-3-(9-xanthen-9-yl) propa-
noic acid), LY367335 (2-Amino-2-(3-cis and trans-carboxycyclobu-
tyl)-3-(9H-xanthen-9-yl) propionic acid), LY367366 ((R,S)-2-amino-
2-(4-carboxyphenyl)-3-(9H-thioxanthen-9-yl) propanoic acid),
and LY339840 ((R,S)-2-methyl-3-hydroxy-4-carboxyphenylgly-
cine), were highly protective against limbic seizures induced by
i.c.v. injection of the mixed mGlu1/5 receptor agonist, 3,5-dihy-
droxyphenylglycine (DHPG) [42]. Zavala-Tecuapetla et al. [43]
examined the effect of the selective mGlu5 receptor NAM,
3-((2-methyl-4-thiazolyl)ethynyl)pyridine (MTEP), in an in vivo
model of complex partial seizures based on repeated electrical
stimulations of the dorsal hippocampus in rats. Treatment with
MTEP suppressed epileptic after discharges in 12- and 18-day-old
rats, but not in 25-day-old rats. Systemic treatment with the
mGlu1 receptor orthosteric antagonist, AIDA, or with the mGlu5
receptor NAM, MPEP, was highly protective against audiogenic
seizures in a genetic rat model of reflex epilepsy [44]. A decrease
in seizure threshold for pentylenetetrazole (PTZ) during diazepam
withdrawal was suppressed by i.c.v. pretreatment with the group
I mGlu receptor antagonist, (S)-4-carboxyphenylglycine ((S)-
4CPG) [45]. In contrast, treatment with mGlu1 or mGlu5 receptor
antagonists (EMQMCM ([3-ethyl-2-methyl-quinolin-6-yl-(4-meth-
oxy-cyclohexyl)-methanone methanesulfonate]) and MPEP,
respectively), did not produce robust anticonvulsant effects in
the 6-Hz test and amygdaloid kindling, twomodels for difficult-to
-treat secondarily generalized focal epilepsies [46]. Taken
together, these data suggest that mGlu1 and mGlu5 receptors
blockers are more effective in models of generalized convulsive
epilepsies than inmodels of partial epilepsies.While all these data
clearly demonstrate that endogenous activation of either mGlu1
or mGlu5 receptors facilitates the generation of convulsive sei-
zures, genetic deletion ofmGlu5 receptors did not protect against
chemically induced seizures in mice [47]. In the same study,
systemic treatment with MTEP did not reduce NMDA-induced
seizures [47]. These findings do not support the hypothesis of
a pro-convulsant activity of mGlu5 receptors in mice. Again, the
complex role of mGlu receptors in the modulation of synaptic
transmission may contribute to provide an explanation for these
conflicting findings.
2.2. Group-I mGlu receptors in models of absence
epilepsy
Expression and function of mGlu1 and mGlu5 receptors have been
extensively investigated in a variety of experimental animalmodels
of absence epilepsy. Absence seizures are non-convulsive seizures
associated with bilateral symmetrical so-called ‘generalized’ spike-
and-wave discharges (SWDs) at the electroencephalogram (EEG),
which are generated by pathological oscillations of a cortico-
thalamo-cortical neuronal network formed by the somatosensory
cortex, the ventrobasal thalamic nuclei, and the reticular thalamic
nuclei [48]. Both genetic epilepsy models and acute pharmacolo-
gical seizure models of absence epilepsy are available. Rats of the
Wistar Albino Glaxo/Rijswijk (WAG/Rij) strain represent a genetic
absence model, and they develop spontaneous absence seizures
after 2–3 months of age [49,50]. We have found that expression
and function ofmGlu1▮ receptorswere reduced in the thalamus of
symptomatic (8-month-old) WAG/Rij rats compared to both age-
matched non-epileptic control rats and young pre-symptomatic
WAG/Rij rats [51]. These findings were confirmed by Karimzadeh
et al. [52], who also found a reduction of mGlu1▮ receptor mRNA
and protein levels in the thalamus of symptomatic WAG/Rij rats.
Expression of mGlu1 receptors was also reduced in the hippocam-
pus of double mutant (zi/zi, tm/tm) spontaneously epileptic rats,
which exhibit both absence-like seizures and tonic convulsions
[53]. Moving from the reduced mGlu1 receptor function found in
the thalamus of symptomatic WAG/Rij rats, we have hypothesized
that pharmacological enhancement of mGlu1receptors could dis-
play ‘therapeutic activity’ against absence seizures. We tested this
hypothesis using compound RO0711401 (9H-xanthene-9-car-
boxylic acid (4-trifluoromethyl-oxazol-2-yl) amide), which behaves
as a selective and brain-permeant mGlu1 receptor positive allos-
tericmodulator (PAM). mGlu receptor PAMs bind to a receptor site
different than the glutamate recognition site (usually in the 7-TM
domains) and amplify receptor response to glutamate acting in an
activity-dependent manner. Systemic administration of low doses
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of RO0711401 (3 or 10mg/kg) significantly reduced the frequency
of occurrence of SWDs in WAG/Rij rats, whereas higher doses
(30 mg/kg) reduced both the frequency and the mean duration
of SWDs. In contrast, administration of the mGlu1 receptor
NAM, JNJ16259685 ((3,4-dihydro-2H-pyranol[2,3-b]quinolin-7yl)
(cis-4-ethoxycycloexyl)methanone)) increased the frequency of
SWD occurrence [51]. Similar data were obtained by Karimzadeh
et al. [52], who found a reduction in the mean duration of SWDs
after intrathalamic infusion of themGlu1/5 receptor agonist, DHPG,
and an increase in the duration and amplitude of SWDs after
infusion of the mGlu1 antagonist, LY367385, in WAG/Rij rats.
These findings suggest that mGlu1 receptors are candidate drug
targets for the treatment of absence epilepsy. However, the evi-
dence that the anti-absence activity of RO0711401 was lost after
the first two days of repeated administration [54] suggests the
development of tolerance, which might be a major drawback in
the therapeutic use of mGlu1 receptor PAMs. Our studies in WAG/
Rij rats indicate also that mGlu5 receptors are a more promising
candidate drug target for the treatment of absence epilepsy.
Similarl to mGlu1 receptors, the expression and function of
mGlu5 were reduced in the thalamus of WAG/Rij rats. This reduc-
tion was also observed in pre-symptomatic WAG/Rij rats, suggest-
ing that mGlu5 receptors lie at the core of the generation of
absence seizures in this strain of rats [55]. Systemic administration
of the mGlu5 receptor PAM, VU0360172 ((N-clyclobutyl-6-[2–3
(fluorophenyl) ethynyl] pyridine-3-carboxamine)), reduced both
the frequency of occurrence and mean duration of SWDs in
WAG/Rij rats, and its action was antagonized by the mGlu5 recep-
tor NAM, MTEP [55]. Interestingly, no tolerance developed to the
anti-absence activity of VU0360172, which was still visible after at
least 10 days of repeated administrations [54]. We have further
explored the mechanism responsible for the anti-absence activity
of mGlu5 receptors by locally administering VU0360172 in the
thalamus or somatosensory cortex of WAG/Rij rats. Injection in
both anatomical sites resulted in a substantial anti-absence activ-
ity. In the cortex, the GABA transporter inhibitor tiagabine acted
similar to the PAM, suggesting that the PAMenhancedGABA-ergic
neurotransmission. Another interesting finding was obtained
when VU0360172 was coinfused with the tiagabine, in the thala-
mus. Intrathalamic injection of tiagabine alone enhanced the fre-
quency of occurrence of SWDs at doses of 1 or 2 µg/µl but was
inactive at the dose of 0.5 µg/µl. However, the inactive dose of
tiagabine prevented the anti-absence effect caused by intrathala-
mic infusion of VU0360172 [56]. This suggested that the anti-
absence activity of mGlu5 receptor activation in the ventrobasal
thalamus was mediated by a mechanism that involved GABA
transport. We now have evidence that pharmacological activation
of mGlu5 receptors enhances the expression of the high-affinity
GABA transporter, GAT-1, in the thalamus (Authors’ unpublished
observation), and we are currently exploring whether activation of
mGlu5 receptors influences the mechanism of tonic synaptic inhi-
bition, which relies on the availability of extrasynaptic GABA.
Studies performed in genetic mouse models of absence
epilepsy do not support the hypothesis that mGlu1 or mGlu5
receptors should be activated to restrain absence seizures.
Accordingly, treatment with mGlu1 or mGlu5 receptor antago-
nists reduced SWDs in lethargic (lh/lh) mice, which represent
an atypical model of absence epilepsy [39,40]. In contrast,
pharmacological blockade of mGlu5 receptors did not affect
SWDs in an acute pharmacological model of absence epilepsy
induced by low doses of PTZ in immature rats [57].
Contrasting data may originate from the use of different mod-
els and different drugs (for example, orthosteric vs. allosteric
ligands).
2.2.1. Group II mGlu receptors and convulsive seizures
An increased expression of mGlu2/3 receptors (presumably
mGlu3 receptors) has been reported in reactive astrocytes
in a rat model of temporal lobe epilepsy induced by angu-
lar bundle electrical stimulation [34]. Transforming-growth
factor-β (TGF-β), a neuroprotective cytokine produced by
astrocytes under the control of mGlu3 receptors [58], was
also up-regulated throughout the hippocampus several
days after induction of status epilepticus in rats [34]. In
humans, an up-regulation of mGlu2/3 receptors was found
in reactive astrocytes of patients with glioneuronal tumors
or cortical focal dysplasia, two conditions associated with
intractable epilepsy [59,60].
Analysis of mGlu2 and mGlu3 receptors in neurons showed
a large reduction in the expression and function of both sub-
types in the hippocampal dentate gyrus and cortex in the
pilocarpine model of chronic epilepsy 24 h after the induction
of status epilepticus (SE) [61]. The transcript of mGlu2 receptors
was still down-regulated in the dentate gyrus of pilocarpine-
treated rats two months after the onset of status epilepticus,
whereas the transcript of mGlu3 receptors returned back to
normal at this time point [62]. This raises the possibility that
a long-lasting reduction in the expression and function of pre-
synaptic mGlu2 receptors causes a sustained increase in gluta-
mate release, thereby contributing to epileptogenesis in the
hippocampus. In contrast, an up-regulation of mGlu3 receptors
in reactive astrocytes might result in an enhanced production of
TGF-β [58] and other neurotrophic factors, thereby protecting
neighbor neurons against seizure-induced damage.
Pharmacological data converge to demonstrate protective
activity of group-II mGlu receptor agonists against convulsive
seizures. Intracerebroventricular infusion of (S)-4-carboxy-
3-hydroxyphenylglycine [(S)-4C3HPG)], a mixed mGlu1▮ receptor
antagonist/mGlu2 receptor agonist, dose-dependently antago-
nized pentylenetetrazol- and methyl-6,7-dimethoxy-4-ethyl-beta
-carboline-2-carboxylate (DMCM)-induced clonic convulsions in
mice [63]. (2S,1ʹR,2ʹR,3ʹR)-2-(2,3-dicarboxycyclopropyl) glycine
(DCG-IV), a group-II mGlu receptor agonist that also interacts
with NMDA receptors, enhanced the threshold for generalized
seizures in kindled rats [64], and attenuated kainate-induced
limbic seizures [65].
Similar data were obtained by second-generation group-II
mGlu receptor agonists, which display high potency, sub-
type-selectivity, and brain penetration. For example, the
mGlu2/3 receptor agonist, (-)-2-oxa-4-aminobicyclo[3.1.0]hex-
ane-4,6-dicarboxylate (LY379268), reduced the behavioral
and electrographic course of acute status epilepticus induced
by pilocarpine in mice [66]. LY354740, another potent
mGlu2/3 agonist clinically developed for the treatment of
generalized anxiety disorder [67], exerted a strong inhibition
of epileptiform activity in rats by reducing the excitability of
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entorhinal neurons that are involved in the generation and
propagation of epilepsy [68]; in addition, LY354740 enhanced
the anticonvulsant effects of diazepam [69]. (2R,4R)-
4-Aminopyrrolidine-2,4-dicarboxylate (2R, 4R-APDC), another
potent and selective mGlu2/3 receptor agonist, showed pro-
tective effects against pilocarpine–induced status epilepticus
in adult rats [70].
Two elegant studies from the same research group [71,72]
addressed the important issue of how group-II mGlu receptor
ligands interact with classical anticonvulsant drugs using the
6-Hz model of psychomotor seizures in mice. In the first study
[71] the Authors were able to demonstrate a pharmacological
synergism between levetiracetam and three drugs that activate
mGlu2 receptors: the selective mGlu2 receptor PAMs, JNJ-
42153605 (3-(Cyclopropylmethyl)-7-(4-phenyl-1-piperidinyl)-8-(tri-
fluoromethyl) [1,2,4]triazolo[4,3-a]pyridine) and JNJ-40411813
(1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone), and
the potent mGlu2/3 receptor agonist, LY404039 ((1R,4S,5S,6S)-
4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-diox-
ide). Subthreshold doses of the three mGlu2 receptor ligands
increased the potency of levetiracetam by >25 fold, whereas
a moderately effective dose of levetiracetam increased the
potency of JNJ-40411813 bymore than 10 fold. This likely reflected
a pharmacodynamic interaction because plasma levels of levetir-
acetam and JNJ-40411813 did not differ when the two drugs were
administered in combination [71]. In the second study [72], the
Authors confirmed the pharmacodynamic synergism between
JNJ-46356479 (8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-
difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine)
and levetiracetam in the 6-Hz test with the aid of isobolographic
analysis, and could also demonstrate a synergism of the two drugs
in the corneal kindling model. Interestingly, there was no syner-
gism between JNJ-40411813 and lamotrigine or valproate, two
drugs that share the ability to inhibit voltage-sensitive sodium
channels. These studies have a high translational value suggesting
that drugs that activate mGlu2 receptors may lower the required
effective dose of levetiracetam, therefore optimizing the risk-to-
benefit ratio of levetiracetam in the treatment of temporal lobe
epilepsy and perhaps other types of epilepsy. Interestingly, JNJ-
40411813 (ADX-71149) is currently being prepared for a Phase 2
clinical study by Addex Therapeutics and Janssen Pharmaceuticals
for the treatment of epilepsy.
2.2.2. Group-II mGlu receptors in models of absence
epilepsy
As opposed to findings obtained inmodels of convulsive seizures,
the role of mGlu2/3 receptors in models of absence epilepsy is
controversial. Using lethargic mice to model absence epilepsy,
BrianMeldrum and his Associates have found that treatment with
the selective mGlu2/3 receptor agonists LY379268 and (-)-2-thia-4
aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY389795) reduced
SWD duration [73].
In contrast, we have found that systemic treatment with
LY379268 enhanced, whereas the preferential mGlu2/3 recep-
tor antagonist, LY341495 ((2S)-2-amino-2-[(1S,2S)-2-carboxy-
cycloprop-1-yl]-3-(xanth-9-yl) propanoic acid), reduced, the
number of SWDs in the WAG/Rij rat model [74]. The contrast-
ing findings obtained in two different models of absence
epilepsy [73,74] are difficult to explain. Traditionally, mGlu2
and mGlu3 receptors have been considered as presynaptic
receptors negatively modulating neurotransmitter release.
However, recent findings suggest that mGlu3 receptors are
also found in postsynaptic elements, where they functionally
interact with mGlu5 receptors. Activation of mGlu3 receptors
boost mGlu5 receptor signaling, and mGlu3 receptor-
dependent long-term depression in the prefrontal cortex
requires the endogenous activation of mGlu5 receptors [12].
It is possible that differences in the expression and/or func-
tion of mGlu2 and mGlu3 receptors in the cortico-thalamo-
cortical network underlying SWDs in lethargic mice, and
WAG/Rij rats contributes to the different outcome of treat-
ments with mGlu2/3 receptor agonists. Experiments with sub-
type-selective modulators (selective PAMs or NAMs of mGlu2
and mGlu3 receptors) should be carried out to unravel the
precise role played by either receptor subtypes in the two
models of absence epilepsy.
2.3. Group-III mGlu receptors and convulsive seizures
For many years, the study of group III mGlu receptors in
epilepsy has been hampered by the lack of subtype-selective
ligands. More recently, the development of both orthosteric
and allosteric ligands targeting individual group-III mGlu
receptor subtypes has encouraged investigation of these
receptors in CNS disorders, including epilepsy [75]. A role for
group-III mGlu receptors in epilepsy is suggested by the evi-
dence that changes in the transcripts of mGlu4 receptors are
found in the hippocampal dentate gyrus of mice developing
limbic seizures in response to pilocarpine. Interestingly,
increases in mGlu4 receptor mRNA levels were found in CD1
mice, but not in FVB/N mice, which are more susceptible to
pilocarpine-induced seizures. Hence, it has been speculated
that mGlu4 receptors might have a protective role against
limbic convulsive seizures in the pilocarpine SE mode [76].
However, this interpretation is not in line with pharmacologi-
cal data showing that i.c.v. treatments with L-2-amino-4-phos-
phonobutanoate (L-AP4) and L-serine-O-phosphate (L-SOP)
(the two prototypical orthosteric agonists of all group-III
mGlu receptor subtypes) are pro-convulsant in both nonepi-
leptic Swiss–Webster and epileptic DBA/2 mice [77]. Curiously,
i.c.v. administration of non-subtype-selective group-III mGlu
receptors antagonists also produced pro-convulsant effects
in these mice [77]. Similar findings were obtained with the
mGlu4 receptor PAM, N-phenyl-7-(hydroxyimino)cyclopropa[b]
chromen-1a-carboxamide (PHCCC), in three models of epilep-
tic seizures in immature rats: PHCCC potentiated the effect of
a sub-convulsant dose of PTZ, significantly prolonged the
duration of PTZ-induced rhythmic activity episodes, and shor-
tened the intervals between individual episodes [78].
In other studies, pharmacological activation of group-III mGlu
receptors produced anticonvulsant effects. For example, the
group-III mGlu receptor agonist, ACPT-1 ((1S,3R,4S)-1-aminocyclo-
pentane-1,2,4-tricarboxylic acid), reduced DHPG-induced seizures
in rats and sound-induced seizures in bothDBA/2mice andgeneti-
cally epilepsy-prone (GEP) rats [79]. Another group-III agonist,
(R,S)-4-phosphonophenylglycine (PPG), displayed anticonvulsant
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activity, and its action was abrogated in mice lacking mGlu7
receptors [80]. (S)-3,4-dicarboxyphenylglycine (DCPG), a selective
agonist of mGlu8 receptors, was able to reduce DL-homocysteic
acid-induced seizures and to suppress clonic-tonic seizures [81]. In
addition, a down-regulation ofmGlu8 receptors has been detected
in pilocarpine-epileptic rats [82]. Clearly, the role played by group-
III mGlu receptor subtypes in the regulation of convulsive seizures
is not homogeneous, andoff-target effects of agonists and antago-
nists used in the various studies cannot be ruled out. While it
appears that mGlu8 and mGlu7 receptors display anticonvulsant
properties, the role ofmGlu4 receptors in the pathophysiology and
control of convulsive seizures remains controversial.
2.3.1. Group-III mGlu receptors in models of absence
epilepsy
A series of findings combining electrophysiological analysis in
thalamic neurons, preclinical models, and genetic studies in
humans suggest that mGlu4 and mGlu7 receptors are involved
in the pathophysiology of absence seizures and can be tar-
geted by therapeutic interventions (reviewed by Ngomba
et al. [83]). A pro-absence activity of mGlu4 receptors is sug-
gested by the evidence that mGlu4 receptor knockout mice
are resistant to absence seizures evoked by low doses of PTZ,
whereas local injection of a mGlu4 receptor agonist in wild-
type mice exacerbated pharmacologically induced absence
seizures [84]. This hypothesis is supported by our studies in
WAG/Rij rats, which showed an increased expression of mGlu4
receptors in the reticular thalamic nucleus as compared to
non-epileptic control rats [85]. In symptomatic WAG/Rij rats,
systemic administration of the mGlu4 receptor PAM, PHCCC,
enhanced the incidence of SWDs [85]. Interestingly, poly-
morphic variants of GRM4, the gene encoding for the mGlu4
receptor, have been associated with juvenile myoclonic epi-
lepsy (JME), an epileptic syndrome belonging to the group of
genetic generalized epilepsies and characterized, inter alia, by
the occurrence of absence seizures [86–88].
The mGlu7 receptor may play a central role in the pathophy-
siology of thalamo-cortical oscillations underlying SWDs and
absence seizures. Federica Bertaso and her Associates from the
Institute of Functional Genomics in Montpellier (France) have
shown that genetic or pharmacological disruption of the mGlu7
receptor or its PDZ-interacting protein, protein interacting with
C kinase 1 (PICK1), causes behavioral and EEG manifestations
typical of absence epilepsy [89]. Mice lacking the PDZ domain of
mGlu7 receptors are also more susceptible to absence seizures
induced by low doses of PTZ [90]. These findings laid the ground-
work for an in-depth study of the role played bymGlu7 receptors
in the pathophysiology of the cortico-thalamo-cortical network.
By combining optogenetics, electrophysiological recordings, and
pharmacology, Tassin et al. [91] have found that mGlu7 receptors
are presynaptically localized in both glutamaterigc and
GABAergic terminals, where they inhibit neurotransmitter release
and short-term synaptic plasticity. Similar findings were obtained
in vitro by Kyuyong and Huguenard [92], who found that high
concentrations of L-AP4, which likely recruit mGlu7 receptors at
reticular thalamic-ventrobasal thalamic synapses, inhibit patho-
logical oscillations underlying absence seizures. Selective phar-
macological blockade of mGlu7 receptors with the NAM,
ADX71743 (6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydrobenzo[d]
oxazol-4(5H)-one), enhanced synaptic transmission in the thala-
mus inducing SWDs at the EEG, and behavioral arrest [91]. Taken
together, these findings raise the interesting possibility that func-
tional alterations in mGlu7 receptors cause pathological oscilla-
tions within the cortico-thalamo-cortical network underlying
absence seizures and that drugs that selectively enhance mGlu7
receptor function might be therapeutically helpful against
absence epilepsy.
3. Conclusion
After many years of extensive research, it is frustrating that no
mGlu receptor ligands are present in the drug market, as yet.
However, many subtype-selective ligands are still under devel-
opment for the treatment of CNS disorders, and the hope that
some of them will be soon available for human use is still alive.
A synopsis of studies showing protective effects with mGlu
receptor ligands in experimental animal models of epilepsy is
shown in Table 1. Synaptic localization and function of individual
mGlu receptor subtypes are shown in Figure 1. mGlu5 receptor
NAMs appear to be promising candidates for the treatment of
convulsive epileptic syndromes, whereas, in our opinion, mGlu5
receptor PAMs may enrich the therapeutic armamentarium for
the treatment of absence epilepsy. It is more often the case that
anti-epileptic drugs have opposite effects on convulsive and
non-convulsive epilepsies. A potential drawback in the use of
mGlu5 receptor NAMs is cognitive dysfunction, which might
result from an impairment of activity-dependent synaptic plasti-
city. In contrast, the neuroprotective activity of mGlu5 NAMs
(reviewed by Nicoletti et al. [9]; Bruno et al. [24]) might restrain
excitotoxic neuronal death occurring in some epileptic syndrome
(e.g., temporal lobe epilepsy associated with Ammon’s horn
sclerosis). The evidence that mGlu5 receptors are anatomically
and functionally linked to NMDA receptors raises the possibility
that a prolonged use of high doses of mGlu5 NAMs may cause
neurodegeneration and psychotomimetic effects [93], which
would seriously limit the development of these drugs in the
treatment of absence epilepsy. The use of biased mGlu5 PAMs,
which amplify mGlu5 receptor function without potentiating
NMDA receptor activity [94], may help overcome this limitation.
The elucidation of the precise mechanisms whereby mGlu5
receptors restrain pathological oscillation within the cortico-
thalamo-cortical network will give the impetus for the develop-
ment of mGlu5 receptor PAMs for the treatment of absence
epilepsy. Moreover, studies aimed towards antiepileptogenesis
in absencemodels (or in any other model for epileptogenesis), as
recently reviewed [95], using mGlu5 PAMs are still lacking.
Preclinical data are still insufficient to conclude that mGlu2/3
ligands could be promising candidate drug targets for the treat-
ment of convulsive or absence epilepsy. However, the pharma-
codynamic synergism between mGlu2 receptor PAMs and
levetiracetam [71,72] holds promise from a therapeutic stand-
point. The recent availability of mGlu2- and mGlu3-selective
NAMs will help to elucidate the precise role of the two receptor
subtypes in the pathophysiology of epilepsy [96–99].
In contrast, mGlu7 receptors appear to be tightly linked to the
pathophysiology of absence epilepsy (at least in animal models),
and, this encourages the development of selective mGlu7 recep-
tor agonists or PAMs for the treatment of this disorder.
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Table 1. Synopsis of studies showing protection with mGlu receptor ligands in experimental animal models of epilepsy.
Subtype Ligand Treatment Animal model Ref.
mGlu1 LY367385 (Ant)
AIDA (Ant)
LY367385 (Ant)
AIDA (Ant)
LY367385 (Ant)
LY339840 (Ant)
AIDA (Ant)
4CPG (mGlu1/5 Ant)
RO0711401 (PAM)
DHPG (mGlu1/5 Ago)
i.c.v.
IColl infusion
i.c.v.
i.p., 1.5 mg/kg
i.c.v.
s.c., 3 or 10 mg/kg
single injection only
IT infusion
Audiogenic seizures in DBA/2 mice
Spontaneous SWDs in lethargic mice
Audiogenic seizures in GEPRs
DHPG-induced seizures
Audiogenic seizures in GEPRs
Diazepam withdrawal
WAG/Rij rats
WAG/Rij rats
39
39
42
44
45
51,54
52
mGlu5 MPEP (NAM)
SIB-1893 (NAM)
MTEP (NAM)
MPEP (NAM)
VU0360172 (PAM)
MPEP (NAM)
i.c.v. or i.p.,
multiple doses
i.p., 20 or 40 mg/kg
i.p., 10 mg/kg
s.c., 3 or 10 mg/kg single and repeated injections
ICtx and IT infusions
i.p., 50 mg/kg
Audiogenic seizures in DBA/2 mice
Hippocampal stimulation
Audiogenic seizures in GEPRs
WAG/Rij rats
lethargic mice
40
43
44
54,55
56
40
mGlu2/3 4C3HPG (Ago)
DCG-IV (Ago)
DCG-IV (Ago)
LY379268 (Ago)
LY354740 (Ago)
2R,4R-APDC (Ago)
LY389795 (Ago)
LY379268 (Ago)
LY404039 (Ago)
JNJ-42153605 (mGlu2 PAM)
JNJ-40411813 (mGlu2 PAM)
JNJ-46356479
LY341495 (Ant)
i.c.v.
i.c.v.
i.c.v.
i.p., 10 mg/kg
i.p., 4–16 mg/kg
i.c.v.
i.c.v. or i.p.
both at multiple doses
s.c., multiple doses
s.c., multiple doses
s.c., multiple doses
s.c., multiple doses
i.p., multiple doses
Clonic seizures by PTZ or DMCM
Amygdaloid kindling
Kainate-induced seizures
Pilocarpine-induced SE
Picrotoxin- and PTZ-induced seizures
Pilocarpine-induced SE
DBA/2 mice, amygdaloid kindling
GEPRs, lethargic mice
6-Hz model and corneal kindling
WAG/Rij rats
63
64
65
66
69
70
73
71,72
74
mGlu4/7/8 ACTP-1 (mGlu4 Ago)
(R,S)-PPG (Ago)
(S)-DCPG (mGlu8 Ago)
i.c.v.
i.c.v.
i.c.v.
DBA/2 mice and GEPRs
PTZ in mice (lost in mGlu7
−/- mice)
L-Homocysteic-induced seizures
79
80
81
Only studies showing protection against seizures with mGlu receptor ligands are reported. For studies showing no effect or aggravation of seizures, see the
appropriate sections in the text.
Ago = orthosteric agonist; Ant = orthosteric antagonist; i.c.v. = intracerebroventricular infusion; i.p. = intraperitoneal injection; IColl infusion = infusion in the
inferior colliculus; ICtx infusion = intracortical infusion; IT infusion = intrathalamic infusion; NAM = negative allosteric modulator; PAM = positive allosteric
modulator; s.c. = subcutaneous administration.
For abbreviations and molecular structures of mGlu receptor ligands and other drugs, see appropriate sections in the text.
Figure 1. Synaptic localization and function of individual mGlu receptor subtypes.
Negative modulation of glutamate release by mGlu2 receptors contributes to explain the encouraging data obtained with mGlu2 receptor PAMs in models of convulsive seizures [71,72].
mGlu5 receptor NAMs may restrain convulsive seizures by inhibiting postsynaptic mGlu5 receptors, which are functionally linked to NMDA receptors (see main text). Positive modulation of
GAT-1 receptors by mGlu5 receptors PAMs is hypothetical and contributes to explain the protective activity of mGlu5 receptor PAMs in the WAG/Rij rat model of absence epilepsy (see main
text). For a more detailed representation of the role played by individual mGlu receptor subtypes in the regulation of the cortico-thalamo-cortical network underlying absence seizures, see
Ref [83]. and [101].
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4. Expert opinion
Although glutamate is a main player of over-excitation in
epilepsy, glutamate receptor antagonists were not success-
fully developed as antiepileptic drugs, with the notable
exception of perampanel. One of the reasons is that iGlu
receptor antagonists are not disease-dependent and cause
a widespread inhibition of excitatory synaptic transmission in
the CNS. In addition, NMDA receptor antagonists impair
mechanisms of activity-dependent synaptic plasticity and
may cause psychotomimetic effects. Targeting mGlu recep-
tors with subtype-selective ligands (particularly, PAMs and
NAMs) might offer a more favorable outcome in the treat-
ment of epilepsy because mGlu receptors do not mediate,
but rather modulate, synaptic transmission. Using these
drugs, we expect a greater selectivity for overexcited neuro-
nal networks (for example, the action of PAMs is activity-
dependent), and a better profile of safety and tolerability.
Metabotropic glutamate (mGlu) receptors were discovered
in 1985. Since then, they have attracted the interest of neu-
roscientists in many different fields with great potential as
candidate drug targets for the treatment of CNS disorders.
Preclinical data and clinical studies carried out in CNS disor-
ders other than epilepsy indicate, in general, a good profile of
safety and tolerability for most mGlu receptor ligands, and this
strengthens the potential value of these drugs in the treat-
ment of epilepsy.
Drugs that inhibit mGlu1 and mGlu5 receptors (either
NAMs or orthosteric antagonists) have consistently shown
protective activity in models of convulsive epilepsy.
However, the potential detrimental effects of mGlu1 receptor
antagonists on cerebellar function [100] and the impact of
mGlu5 NAMs on mechanisms of activity-dependent synaptic
plasticity (see above) may limit the use of these drugs in the
treatment of epilepsy. The exciting data obtained with the
6-Hz model of psychomotor seizures [71,72] suggest that
mGlu2 receptor PAMs are promising candidate drugs for the
treatment of focal epilepsy and may act synergistically with
levetiracetam, one of the most widely used drugs in epilepsy.
Although the molecular nature of this pharmacodynamics
interaction is unknown, these findings are highly promising
from a therapeutic standpoint.
Our data obtained in WAG/Rij rats (a well-developed and
validated model of absence epilepsy) encourage the devel-
opment of mGlu5 PAMs for the treatment of absence sei-
zures. These drugs might act by enhancing GABA reuptake
in ventrobasal thalamic nuclei. These drugs suppress SWDs
both in cortex and in thalamus. In the cortex by stimulating
GABA-ergic interneurons, in the ventrobasal thalamic nuclei
by enhancing GABA-ergic reuptake. mGlu5 PAMs are under
development for the treatment of schizophrenia and dis-
play cognitive enhancing effects in rodents. Stimulus-biased
mGlu5 receptor PAMs that do not activate NMDA receptors
show no neurotoxic effects in rodents and are particularly
promising from a therapeutic standpoint. We predict that
drugs that selectively activate mGlu7 receptors are effective
in the treatment of absence epilepsy. Both mGlu5 and
mGlu7 PAMs might be clinically helpful in patients that
are refractory to conventional medications and require
polytherapy for an adequate control of absence seizures.
Thus, the study of mGlu receptors in epilepsy represents an
exciting example of translational research that holds pro-
mise for the treatment of one of the most common CNS
disorders which is a high social and economic burden
worldwide.
A dark side is that the role of mGlu receptors in mechan-
isms of epileptogenesis is lacking, and, in general, most of the
existing data were obtained after acute or temporally
restricted administration of mGlu receptor ligands, whereas
drug treatment of epilepsy in humans usually lasts for several
months or years (except for emergency treatment of SE). It will
be extremely interesting to examine the effect of mGlu recep-
tor ligands on epileptogenesis in genetic and kindling models
of epilepsy, and to investigate whether chronic treatments
with these drugs restrains the development or recurrence of
seizures (for example, by treating pre-symptomatic WAG/Rij
rats with mGlu5 receptor PAMs or by administering appropri-
ate receptor ligands after SE during the so-called ‘silent’ period
in the pilocarpine and kainic acid models).
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